According to a press release on November 2, 2012, the Food and Drug Administration (FDA) is continuing to review data regarding the safety of the pharmaceutical anticoagulant Pradaxa. Using insurance claims and administrative data, the FDA determined that the bleeding risks associated with new Pradaxa use did not appear to be greater than the bleeding risks associated with new use of warfarin. The FDA has not changed its recommendations regarding Pradaxa.
However, the FDA has not addressed the issue of the lack of antidote for Pradaxa bleeds. In contrast to other anticoagulant pharmaceuticals such as warfarin (Coumadin, Jantoven, and generics), bleeding associated with Pradaxa cannot be counteracted by the administration of Vitamin K. Healthcare professionals are urged to carefully follow the dosing recommendations for Pradaxa, especially for patients with renal impairment.
For more information, contact the Ohio Pradaxa lawyers at Clark, Perdue & List.
Source: Food and Drug Administration MedWatch, “Pradaxa (dabigatran etexilate mesylate): Drug Safety Communication – Safety Review of Post-Market Reports of Serious Bleeding Events,” November 2, 2012.
Have questions about your legal situation?
Speaking with an experienced attorney can make all the difference. Our team is ready to listen, evaluate your case, and explain your options clearly.
📞 Call us today at (614) 469-1400 for a free, confidential consultation.
Disclaimer: The information provided in this article is for general informational purposes only and does not constitute legal advice. Every case is unique, and laws are subject to change. Reading this article does not create an attorney-client relationship. Please consult with a qualified attorney regarding your specific legal situation.
Share With Your Colleagues